This Insider Has Just Sold Shares In Applied Therapeutics
This Insider Has Just Sold Shares In Applied Therapeutics
Some Applied Therapeutics, Inc. (NASDAQ:APLT) shareholders may be a little concerned to see that the Chair of the Board of Directors, Shoshana Shendelman, recently sold a substantial US$4.7m worth of stock at a price of US$6.06 per share. That's a big disposal, and it decreased their holding size by 15%, which is notable but not too bad.
看到董事長Shoshana Shendelman最近以每股6.06美元的價格大舉售出470萬美元的股票,一些Applied Therapeutics, Inc.(納斯達克代碼: APLT)股東可能會有點擔心。這是一次大規模的拋售,減少了他們的持股比例15%,儘管有些顯著,但並不算太糟糕。
The Last 12 Months Of Insider Transactions At Applied Therapeutics
應用療法內部交易的最後12個月
In fact, the recent sale by Shoshana Shendelman was the biggest sale of Applied Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at around the current price of US$5.85. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
事實上,根據我們的記錄,Shoshana Shendelman最近的出售是Applied Therapeutics股票內部個人在過去12個月中所做的最大銷售。這意味着某個內部人士正在以約每股5.85美元的價格出售股票。雖然我們通常不喜歡看到內部人士出售股票,但如果銷售以更低的價格發生,那就更令人擔憂。我們注意到這次出售價格大約在現價左右,所以並不是一個主要問題,儘管也不是一個好的跡象。
Over the last year we saw more insider selling of Applied Therapeutics shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在過去一年中,我們看到了更多的應用療法股票內部人士出售股票,而非購買。您可以在下面看到內部交易(由公司和個人)在過去12個月中的視覺描述。如果單擊圖表,您可以查看所有個別交易,包括股票價格、個人和日期!
![big](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240817/0-7cc8654b16360fee8bc95e5303ef2ac5-0-7a64a493300c8c7925c1dcf56b6015a0.png/big)
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。
Insider Ownership Of Applied Therapeutics
應用療法股票內部所有權
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 6.1% of Applied Therapeutics shares, worth about US$41m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
許多投資者喜歡檢查公司內部人士擁有多少股份。如果內部人士擁有公司的大量股票,那麼這是一個好的跡象。內部人士擁有應用療法股票6.1%,價值約4100萬美元。內部所有權水平很高,但尚未達到特別突出的水平。它一定表明了合理的對齊程度。
What Might The Insider Transactions At Applied Therapeutics Tell Us?
Applied Therapeutics的內部交易可能告訴我們什麼?
Insiders haven't bought Applied Therapeutics stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example, Applied Therapeutics has 4 warning signs (and 2 which are concerning) we think you should know about.
在過去三個月內,內部人士並沒有購買應用療法股票,但有部分銷售。儘管有一些內部人士購買,但長期情況並沒有讓我們感到更加積極。內部所有權並不是特別高,因此我們對公司持謹慎態度。因此,在仔細考慮之後,我們才會買入。雖然了解內部所有權和交易的情況很重要,但在做出任何投資決策之前,我們還會考慮股票面臨的風險。例如,應用療法股票有4個警告信號(和2個令人擔憂的信號),我們認爲您應該知道。
But note: Applied Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
需要注意的是:應用療法可能不是最好的投資股票。因此,請查看此免費列表,其中包含具有高roe和低債務的有趣公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。